Searched for
LUPIN QUARTERLY EARNINGS
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Suryoday Small Finance Bank reports Q4 profit at Rs 49 croreSuryoday Small Finance Bank reported a strong turnaround in fourth-quarter earnings with improved profitability and higher operating profit...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Stocks in news: HDFC Bank, ICICI Bank, RIL, Trent, Jio FinancialIndian markets are set for a dynamic start today. Investors will closely watch the Q4 results from banking giants HDFC Bank and ICICI Bank....
- Time to buy? Sunny Agrawal finds best picks across banking, pharma, capital markets & infrastructureIndian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...
- Lupin Q1 Results: Net profit surges 77% to Rs 801 croreLupin Q1 Results: Lupin's consolidated net profit surged by 77% to Rs 801 crore in the first quarter ending June 30, 2024, fueled by strong...
- Lupin Q3 Results: Net profit declines 72% YoY to Rs 153.5 croreThe earnings before interest, tax, depreciation and amortisation (EBITDA) increased 44% YoY to Rs 532.7 crore for the quarter, with EBITDA ...
- Neutral on Lupin, target price Rs 1320: Motilal OswalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 55707.38 Crore) operating in Pharmaceuticals s...
- Neutral on Lupin, target price Rs 1320: Motilal OswalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 54321.39 Crore) operating in Pharmaceuticals s...
- Trending stocks: Lupin shares gain nearly 1%A total of 15,727 shares changed hands on the counter till 09:36AM.
- Lupin's weak Q1 nos take toll: Brokerages cut target priceAnalysts expect the current financial year to be challenging for the company in terms of US sales.
- Credit Suisse sees Lupin’s EPS hit as Fortamet, Glumetza losing volume sharePrescriptions for Fortamet and Glumetza market are down 13% QoQ (quarter on quarter), which could impact FY18 EPS for Lupin by 5%.
- Underperform Lupin Ltd., target Rs 1500.0 : CLSAThe competition in the top US products segment is likely to weigh on Lupin's FY18 EPS growth, said the CLSA note.
- It may take another quarter for Lupin to post a robust showMumbaibased pharma company Lupin has posted better-than-expected numbers after reporting dismal figures for four successive quarters.
- Rising local sales, strong drug pipeline may nurse Lupin back to healthAfter a stellar show in earlier years, where it grew an average 20 per cent annually , it has been difficult for Lupin to sustain growth.
- Local manufacturing can boost margins for LupinFor a fairly consistent performer in terms of top line growth in the pharma industry, drug maker Lupin’s show in the quarter to December wa...
- This growth co is commanding fair valuationsFuelled by strong growth across its various business segments, Lupin’s third quarter performance beat the market expectations.
Load More
